Rilparencel (Renal Autologous Cell Therapy-REACT®) for Chronic Kidney Disease and Type 1 and Type 2 Diabetes: Phase 2 Trial Design Evaluating Bilateral Kidney Dosing and Redosing Triggers.
Joseph StavasArnold L SilvaThomas D WooldridgeAhmed AqeelTheodore SaadRachita PrakashGeorge BakrisPublished in: American journal of nephrology (2024)
The trial is fully enrolled with fifty-three participants. Cell injections and follow-up clinical visits are ongoing. This multicenter phase 2 RCT is designed to investigate the efficacy and safety of rilparencel with bilateral kidney dosing and compare two injection schedules with the potential of preserving or improving kidney function and delaying kidney disease progression among patients with stages 3a-4 CKD with diabetes.
Keyphrases
- cell therapy
- chronic kidney disease
- type diabetes
- stem cells
- mesenchymal stem cells
- end stage renal disease
- glycemic control
- cardiovascular disease
- ultrasound guided
- study protocol
- case report
- clinical trial
- bone marrow
- single cell
- insulin resistance
- phase iii
- human health
- risk assessment
- weight loss
- peritoneal dialysis